Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

AUSTIN, Texas, May 19, 2021 – Lumos Pharma (NASDAQ:LUMO), a biopharmaceutical company focused on rare disease therapeutics, announced participation in the Jefferies Virtual Healthcare Conference on June 3, 2021. The company will conduct a live fireside chat from 3:30 PM to 3:55 PM ET and host one-on-one meetings with investors. The chat can be accessed via the conference link and will be available for replay for 30 days on the company’s website. Lumos Pharma is advancing LUM-201, a growth hormone therapy under Phase 2b trial for Pediatric Growth Hormone Deficiency.

AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021 and will be hosting virtual one-on-one meetings with investors during the conference.

Event:		Jefferies Virtual Healthcare Conference
Date:		June 3, 2021
Time:		Live Fireside Chat 3:30 PM – 3:55 PM (ET)

The live Lumos Pharma fireside chat can be accessed through the link Jefferies Virtual Healthcare Conference. The link can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay will be available for 30 days. Please contact your Jefferies salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

When is Lumos Pharma's fireside chat at the Jefferies Virtual Healthcare Conference?

Lumos Pharma's fireside chat is scheduled for June 3, 2021, from 3:30 PM to 3:55 PM ET.

How can I access the Lumos Pharma fireside chat?

The Lumos Pharma fireside chat can be accessed through the Jefferies Virtual Healthcare Conference link, available on their website.

What is the focus of Lumos Pharma's development?

Lumos Pharma focuses on developing therapeutics for rare diseases, particularly for Pediatric Growth Hormone Deficiency.

What is LUM-201 and its significance?

LUM-201 is Lumos Pharma's lead therapeutic candidate, aimed at providing an oral alternative to growth hormone injections for treating Pediatric Growth Hormone Deficiency.

What designation has LUM-201 received?

LUM-201 has received Orphan Drug Designation in both the US and EU.